Combining New Therapies and MRD Approaches Across Lymphomas

Exciting developments in follicular lymphoma treatment are on the horizon, with ongoing trials exploring the combination of bispecific antibodies with chemotherapy or chemoimmunotherapy in initial treatments and experimenting with dose-limited or time-limited therapies. Future research may increasingly focus on minimal residual disease (MRD)-directed approaches, potentially allowing for earlier or reduced treatment based on MRD testing outcomes. As these advancements continue, more refined and effective treatment strategies are expected, including a broader adoption of newer agents like bispecific antibodies and evolving chimeric antigen receptor T-cell therapies, tailored to patient specific needs and improving long-term outcomes.

Julie Vose, MD, chief of the division of oncology and hematology at the University of Nebraska Medical Center/Nebraska Medicine, discusses the exciting developments across lymphomas.

Read more in a special report coming out this September!

• #education
• #targeted_oncology
• #oncology
• #cancer